The University of Osaka Hospital
Suita, Osaka, Japan
27 recruiting
Showing 1–20 of 57 trials
Recruiting
Phase 3
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
Metabolic Dysfunction-Associated Steatohepatitis
Boehringer Ingelheim1,590 enrolled444 locationsNCT06632457
Recruiting
Phase 3
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Metabolic dysfunction-associated steatohepatitis (MASH)Liver Fibrosis
Boehringer Ingelheim1,800 enrolled525 locationsNCT06632444
Recruiting
Phase 1Phase 2
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Metastatic Renal Cell CarcinomaCarcinoma, Renal CellAdvanced Renal Cell Carcinoma+10 more
Pfizer224 enrolled128 locationsNCT07227415
Recruiting
Phase 3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
Obesity or Overweight
Hoffmann-La Roche2,000 enrolled164 locationsNCT07351045
Recruiting
Phase 2Phase 3
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
Untreated, Unresectable, or Metastatic Colorectal Cancer
Bristol-Myers Squibb990 enrolled281 locationsNCT07221357
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
CRC (Colorectal Cancer)
Incyte Corporation700 enrolled255 locationsNCT07284849
Recruiting
Phase 3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
Obesity or OverweightType 2 Diabetes Mellitus
Hoffmann-La Roche1,600 enrolled163 locationsNCT07351058
Recruiting
Phase 3
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
HR+/HER2- Breast Cancer
BeOne Medicines1,056 enrolled74 locationsNCT07492641
Recruiting
Phase 3
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Amgen750 enrolled144 locationsNCT07213674
Recruiting
Phase 1
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
Gastric AdenocarcinomaPancreatic AdenocarcinomaGastroesophageal Junction (GEJ) Adenocarcinoma
Astellas Pharma Global Development, Inc.398 enrolled46 locationsNCT05365581
Recruiting
Phase 2
Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers
Gastrointestinal Cancers
Genmab160 enrolled2 locationsNCT07539311
Recruiting
Phase 2Phase 3
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Bristol-Myers Squibb690 enrolled161 locationsNCT07221149
Recruiting
Phase 3
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Metabolic Dysfunction-Associated Steatotic Liver Disease
Eli Lilly and Company4,500 enrolled563 locationsNCT07165028
Recruiting
Phase 2
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
Cognitive DysfunctionLewy Body DiseaseAmyloid+1 more
Eli Lilly and Company350 enrolled72 locationsNCT07589595
Recruiting
Phase 3
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Ovarian NeoplasmsNeoplasm MetastasisFallopian Tube Neoplasms+1 more
Eli Lilly and Company1,630 enrolled266 locationsNCT07213804
Recruiting
Phase 3
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Breast NeoplasmsNeoplasm Metastasis
Eli Lilly and Company800 enrolled346 locationsNCT07174336
Recruiting
Phase 2
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
Ulcerative Colitis (UC)Ulcerative Colitis, Active ModerateUlcerative Colitis, Active Severe
Eli Lilly and Company1,431 enrolled258 locationsNCT07415044
Recruiting
Phase 1
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Breast NeoplasmsStomach NeoplasmsColorectal Neoplasms+4 more
Eli Lilly and Company421 enrolled31 locationsNCT07114601
Recruiting
Phase 3
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer MetastaticNon-Small-Cell Lung CarcinomaNon-small Cell Carcinoma
Pfizer680 enrolled402 locationsNCT07144280
Recruiting
Phase 3
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
Metastatic Colorectal Cancer
Amgen450 enrolled291 locationsNCT06252649